Live Breaking News & Updates on Key Cardio Metabolic|Page 1

Stay updated with breaking news from Key cardio metabolic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

In Akero Therapeutics' Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks

50mg (41%) and 28mg (39%) groups demonstrated =1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution ....

United States , Sarah Oconnell , Andrew Cheng , Linkedinand Twitterfor , Stephen Harrison , Christina Tartaglia , Pa Fibroscan , Exchange Commission , Akero Therapeutics Inc , Pinnacle Clinical Research , Liver Fat , Key Markers , Change From Baseline , Fat Fraction , Key Cardio Metabolic , Conference Call , Private Securities Litigation Reform Act , Annual Report , Quarterly Report ,